Home > Riviste > Panminerva Medica > Fascicoli precedenti > Panminerva Medica 1998 June;40(2) > Panminerva Medica 1998 June;40(2):110-5





Rivista di Medicina Interna

Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6




Panminerva Medica 1998 June;40(2):110-5

lingua: Inglese

Clinical effi­ca­cy and tol­er­ance of nabu­me­tone in artic­u­lar and non-artic­u­lar rheu­mat­ic dis­or­ders: per­son­al expe­ri­ence dur­ing 12 ­weeks of treat­ment

Coaccioli S., Allegra A., Di Cato L., Puxeddu A.

From the Department of Internal Medicine and Rheumatology Medicine “S. Maria” Hospital, Terni, Italy


Background. We eval­u­at­ed the clin­i­cal effi­ca­cy and the tol­er­ance of Nabumetone (N), in com­par­i­son ­with a ­pool of non-ster­oid­al ­anti-inflam­ma­to­ry ­drugs (NSAIDs), in a ­cohort of ­patients affect­ed by rheu­ma­toid ­arthritis, oste­oar­thritis, non-artic­u­lar rheu­ma­tisms and pri­mary fibro­myal­gic syn­drome.
Methods. One hun­dred and sev­en­ty ­patients ­were ­observed in an ­open-non ran­dom­ized ­study. The ­patients ­have ­been recruited alter­na­tive­ly and sub­di­vid­ed into two ­groups: 84 ­patients ­that ­received N and 86 ­patients ­that ­received one of the oth­er NSAIDs. All the ­patients affect­ed by rheu­ma­toid ­arthritis ­received a dis­ease-mod­i­fy­ing ­anti-rheu­mat­ic ­drug (OH-chlor­o­quine, d-pen­i­cil­la­mine, auran­o­fin, cyclo­spo­rine-A); ­while ben­zod­i­az­e­pines are admin­is­tered in the ­patients suf­fer­ing ­from pri­mary fibro­myal­gic syn­drome. A fol­low-up not infe­ri­or to 12 con­sec­u­tive ­weeks was real­ized and the fol­low­ing clin­i­cal param­e­ters ­were stud­ied: spon­ta­ne­ous ­pain, pro­voked ­pain, ­pain on ­active move­ment, ­pain on pas­sive move­ment, ­pain at ris­ing, ­pain at bed ­time, morn­ing stiff­ness, lim­it­ed ­joint mobil­ity, num­ber of ten­der ­points, num­ber of affect­ed ­joints and num­ber of swol­len ­joints. All the ­patients ­were moni­tor­ed for hemat­o­log­i­cal, bio­chem­i­cal, uri­nary and clot­ting ­tests.
Results. The ­results ­revealed an excel­lent tol­er­abil­ity of nabu­me­tone ­with a clin­i­cal effi­ca­cy not infe­ri­or to the NSAIDs’ ­pool. Moreover, the num­ber of ­drop-outs in the N-­group ­were sig­nif­i­cant­ly infe­ri­or in com­par­i­son to the NSAIDs’-­pool ­group.
Conclusions. We con­clude ­that N can be con­sid­ered as effec­tive as oth­er NSAIDs. Moreover it ­seems to be bet­ter tol­er­at­ed ­that the oth­er NSAIDs util­i­zed in our ­study.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail